# Assurant, Inc. (AIZ)

> Source: Nexqual · https://nexqual.com/AIZ · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Assurant, Inc. (AIZ), nexqual.com/AIZ" · informational, not investment advice.

**Price:** USD 288.85 (+1.60% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 284.3 · day 285.42–289.32 · 52w 206.03–303.94 · market cap $14.2B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $13.5B, net income $1.06B (7.9% margin), free cash flow $1.66B (SEC filings).
- Valuation: P/E 13.4x (avg 14.2x at the last 3 fiscal year-ends).
- Insider open-market sales, last ~7 months: 5 Form 4 filings, $10.4M; 3 not under a Rule 10b5-1 plan ($2.2M); 3 by opportunistic insiders (2 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.57 on a 1–5 scale) (7 analysts), mean target USD 326.67 (range 300–355).
- Total return with dividends: 1Y +38.5% vs S&P 500 +14.9%; 5Y +89.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 4.71, revenue estimate $3.45B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $10.2B | $10.2B | $11.1B | $11.9B | $12.8B | $13.5B |
| Net income | $1.36B | $277M | $643M | $760M | $873M | $1.06B |
| EPS (diluted) | $22.66 | $5.05 | $11.95 | $14.46 | $16.93 | — |
| Free cash flow | $594M | $411M | $936M | $1.11B | $1.60B | $1.66B |
| Net margin | 13.4% | 2.7% | 5.8% | 6.4% | 6.8% | 7.9% |
| Revenue growth | +6.1% | +0.1% | +9.2% | +6.7% | +7.9% | — |
| Cash + short-term investments | — | $1.54B | $1.63B | $1.81B | $1.83B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 13.4x · P/S 1.1x · P/FCF 8.6x · P/B 2.3x · FCF yield 11.62% · Earnings yield 7.46% · Dividend yield (paid, TTM) 1.24% · Buyback yield (TTM) 2.65%
P/E at fiscal year-ends: Dec 2025 14.1x, Dec 2024 14.6x, Dec 2023 14.0x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
2 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Biju Nair | EVP, Pres, Global Conn Living | 3,931 | $1.2M | 14% | No | Too little history (no open-market trades in 2023) |
| 2026-06-22 | Lonergan Robert | EVP, CSTO | 7,000 | $1.8M | 20.4% | Yes (adopted March 20, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-26 | Dirienzo Dimitry | SVP, CAO, Controller | 2,000 | $511K | 42.2% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-15 | Meier Keith | EVP, Chief Financial Officer | 25,000 | $6.4M | 56.3% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-14 | Rosenblum Jay | EVP, Chief Legal Officer | 2,000 | $504K | 13.5% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.57 on a 1–5 scale), 7 analysts; mean target USD 326.67 (low 300, high 355).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-06 | Morgan Stanley | Target lowered | Overweight | $320 → $300 |
| 2026-08-28 | BMO Capital | Target raised | Outperform | $274 → $320 |
| 2026-08-19 | Morgan Stanley | Target raised | Overweight | $300 → $320 |
| 2026-08-13 | UBS | Target raised | Buy | $274 → $331 |
| 2026-08-07 | Keefe, Bruyette & Woods | Target raised | Outperform | $310 → $325 |
| 2026-08-06 | Piper Sandler | Target raised | Overweight | $290 → $329 |
| 2026-08-06 | Truist Securities | Target raised | Buy | $310 → $355 |
| 2026-07-08 | Keefe, Bruyette & Woods | Target raised | Outperform | $270 → $310 |
| 2026-07-06 | Morgan Stanley | Target raised | Overweight | $285 → $300 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +38.5% | +89.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +38.7% | +13.6% |
| Volatility (annualized) | 22.2% | 23.8% |
| Max drawdown | -12.9% (Aug 2026→Sep 2026) | -43.5% (Apr 2022→Mar 2023) |

## Peers (Insurance - Property & Casualty)
CNA (CNA Financial Corporation) USD 49.39 +2.21% · AFG (American Financial Group, Inc.) USD 153.46 +2.53% · ORI (Old Republic International Corp) USD 40.08 -0.12% · KNSL (Kinsale Capital Group, Inc.) USD 390.64 +3.70% · L (Loews Corporation) USD 113.68 +1.75% · MKL (Markel Group Inc.) USD 1,905.39 +1.79%

## More
Full page: https://nexqual.com/AIZ · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Global Lifestyle | $490.3M | 14.2% | +21.9% |
| Global Housing | $36.9M | 1.1% | +1.7% |
| Total revenue | $3.45B | 100% | — |
The lines above cover 15.3% of total revenue.

## Revenue by region (fiscal year ended 2025-12-31)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $10.55B | 82.3% | +7.5% |
| Non Us | $2.27B | 17.7% | +9.9% |
| Total revenue | $12.81B | 100% | — |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $4.71 | $4.47 | +5.5% | $3.45B | 7 |
| Next quarter (ends 2026-12-31) | $5.35 | $5.49 | -2.5% | $3.56B | 6 |
| Current fiscal year (ends 2026-12-31) | $22.47 | $21.09 | +6.5% | $13.88B | 7 |
| Next fiscal year (ends 2027-12-31) | $23.45 | $22.56 | +4.0% | $14.62B | 7 |